News - Markets & Marketing, Oncology

Filter

Popular Filters

1 to 25 of 199 results

New entrants in chronic lymphocytic leukemia will raise market value to $3.3 billion by 2018

New entrants in chronic lymphocytic leukemia will raise market value to $3.3 billion by 2018

02-07-2014

The introduction of several new drugs will accelerate growth in the chronic lymphocytic leukemia treatment…

EuropeidelalisibImbruvicaMarkets & MarketingOncologyPharmaceuticalUSA

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

01-07-2014

The cancer immunotherapy market will experience considerable growth through 2022, increasing from $1.1…

AstraZenecaBristol-Myers SquibbEuropeJapanMarkets & MarketingMED14736Merck & ConivolumabOncologypembrolizumabPharmaceuticalResearchRocheUSAYervoy

Cipla links with Hetero for biosimilar Aranesp; M&A in Yemen

30-06-2014

Cipla has collaborated with fellow Indian drugmaker Hetero to launch a biosimilar of the drug darbepoetin…

ActoriseAmgenAranespBiosimilarsCiplaGenericsHeteroIndiaMarkets & MarketingMergers & AcquisitionsOncologyRest of the World

Intas reinforces cancer range with the first time launch of Azadine in India

25-06-2014

Indian drugmaker Intas Pharmaceuticals says it has reinforced its oncology product range by successfully…

AzadineCelgeneGenericsIndiaIntas PharmaceuticalsMarkets & MarketingOncologyVidaza

Physicians views on EGFR wild-type/untested NSCLC treatment

Physicians views on EGFR wild-type/untested NSCLC treatment

20-06-2014

According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential…

AstraZenecaBiotechnologyBristol-Myers SquibbEuropeHealthcareMarkets & MarketingMerck & ConivolumabOncologyOno PharmaceuticalpembrolizumabselumetinibUSA

Doomed future for Tykerb in breast cancer arena, says analyst

Doomed future for Tykerb in breast cancer arena, says analyst

16-06-2014

The future of Tykerb (lapatinib) in the breast cancer market looks bleak, after the combination of GlaxoSmithKline’s…

BiotechnologyGlaxoSmithKlineMarkets & MarketingNovartisOncologyResearchTykerb

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

12-06-2014

The glioblastoma multiforme (GBM) treatment market is forecast to expand rapidly from a value of $301…

Celldex TherapeuticsCotaraDCVaxMarkets & MarketingNorthwest BiotherapeuticsOncologyPeregrine PharmaceuticalsPharmaceuticalResearchrindopepimut

China’s FDA warns of on-line sales of fake cancer drug

China’s FDA warns of on-line sales of fake cancer drug

12-06-2014

China's drug administration on Wednesday warned consumers not to purchase illegally imported cancer drugs…

ChinaMarkets & MarketingOncologyPharmaceuticalRegulation

Mylan launches generic Paraplatin Injection in USA

Mylan launches generic Paraplatin Injection in USA

09-06-2014

US generics major Mylan has launched carboplatin injection, 50mg/5ml, in multi-dose vials, which is the…

Bristol-Myers SquibbGenericsMarkets & MarketingMylanOncologyParaplatinRegulationUSA

Hospira refutes high pricing of paclitaxel during drug shortage

Hospira refutes high pricing of paclitaxel during drug shortage

08-06-2014

The Canadian subsidiary of USA-based injectable generic drugs specialist Hospira has refuted press reports…

CanadaGenericsHospiraMarkets & MarketingOncologyPaclitaxelPricing

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Roche may lose $240 million contract in Russia to Biocad biosimilar

Roche may lose $240 million contract in Russia to Biocad biosimilar

07-05-2014

Swiss drug major Roche may lose an important $240 million contract in Russia for the supply of its anti-cancer…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRegulationrituximabRoche

Modest growth expected for pancreatic cancer therapy market

30-04-2014

Fueled by the increasing global prevalence of pancreatic cancer (PC), coupled with the approval of at…

Markets & MarketingMerrimack PharmaceuticalsMM-398OncologyPharmaceuticalResearchTH-302Threshold Pharmaceuticals

US oncologists prescribing of Boehringer's Gilotrif for NSCLC

25-04-2014

Just six months post-launch in the USA, 49% of surveyed US medical oncologists have prescribed German…

Boehringer IngelheimGilotrifMarkets & MarketingOncologyPharmaceuticalUSA

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11-04-2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

BiotechnologyEuropeGilead SciencesidelalisibImbruvicaJohnson & JohnsonMarkets & MarketingOncologyUSA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

08-04-2014

US biotech firm Seattle Genetics says it will receive milestone payments from Japan’s Takeda Pharmaceutical…

AdcetrisAsia-PacificBiotechnologyFinancialMarkets & MarketingOncologySeattle GeneticsSouth AmericaTakeda Pharmaceuticals

Promising emerging agents for triple negative breast cancer

08-04-2014

Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development…

Astellas PharmaBiotechnologyMarkets & MarketingMedivationniraparibOncologyTesaroXtandi

Pharmaceutical companies to benefit from new blood cancer drugs

04-04-2014

Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

01-04-2014

The global pancreatic cancer treatment market value in the six major countries (6MM: the USA, France,…

AbraxaneBiotechnologyCelgeneEuropeMarkets & MarketingOncologyUSA

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

28-03-2014

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

1 to 25 of 199 results

Back to top